Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Octreotide acetate microspheres - CSPC Pharmaceutical Group

Next Previous
Drug Profile

Octreotide acetate microspheres - CSPC Pharmaceutical Group

Alternative Names: Octreotide acetate microspheres for injection; SYHX-2008; SYHX2008 injection

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC Pharmaceutical Group
  • Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
  • Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acromegaly
  • No development reported Solid tumours

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours in China (Parenteral, Injection)
  • 17 Jul 2024 CSPC Pharmaceutical Group plans a phase II trial for Neuroendocrine tumours (Second-line therapy or greater, Late-stage disease) (SC, injection) in August 2024 (NCT06505395)
  • 28 Jun 2023 CSPC ZhongQi Pharmaceutical Technology completes a phase-I clinical trials in Acromegaly (In volunteers) in China (IM) (NCT05761431)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top